j & j eats itself, page-117

Hello LOPEZ

I realize this is a little delayed, but I note your earlier comment that "revenue from ordinary activities was down 68% last financials." You imply that this is related to a downturn in Elixia sales with your following comment "If you think that Myers and Target can turn that around good on ya." BTW, don't go looking for Elixia at Target because it's not sold there.

This implication reflects an earlier (moderated) comment you made.

I would like to clarify two aspects of this "68% down" reference.

Firstly, the company's June 2011 financials (the last financials) explain that revenues were decreased by 68% due mainly to one-off payments related to ProPhase Labs in the 2010 financial year. Sales revenue figures in the financials actually show an increase of over 302% ( $398,000 to $1,204,000) and product sales, which was what you were actually discussing, increased year on year by 203% (Notes on operating and financial review).

Secondly, one must remember that Elixia Mark II had only been launched last April and BodyShaper in May.

Taking these pertinent facts into account, a 203% year on year increase in product sales could be considered an excellent result.